Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 878 Results

Title
Intervention Indication Therapeutic Area Year Actions
Atezolizumab with platinum-based chemotherapy and bevacizumab for epithelial ovarian cancer or fallopian tube cancer or primary peritoneal cancer Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) , Chemotherapy Epithelial ovarian cancer , Fallopian tube cancer , primary peritoneal cancer Female Reproductive Cancer 2022 View  |  Download
Atezolizumab with chemotherapy for treating recurrent triple-negative breast cancer Atezolizumab (Tecentriq; MPDL3280A) , Chemotherapy Breast cancer Breast Cancer 2022 View  |  Download
Atezolizumab with cabozantinib for previously treated metastatic castration-resistant prostate cancer Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Prostate cancer Male Reproductive Cancer 2022 View  |  Download
Atezolizumab with cabozantinib for advanced renal cell carcinoma after 1 therapy Atezolizumab (Tecentriq; MPDL3280A) , Cabozantinib (XL-184; Cabometyx; Cometriq; XL 184) Renal cell carcinoma (RCC) Renal Cancer 2022 View  |  Download
Atezolizumab with bevacizumab for patients with resected or ablated hepatocellular carcinoma who are at high risk for disease recurrence Atezolizumab (Tecentriq; MPDL3280A) , Bevacizumab (Avastin; R 435; RG 405; RG 435) Hepatocellular carcinoma (HCC) Gastrointestinal Cancer 2022 View  |  Download
Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer – first line Atezolizumab (Tecentriq; MPDL3280A) Urothelial cancer Urological Cancer 2020 View  |  Download
Atezolizumab in combination with Nab-paclitaxel for unresectable, locally advanced or metastatic triple-negative breast cancer – first line Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) Breast cancer Breast Cancer 2018 View  |  Download
Atezolizumab in combination with nab-paclitaxel as neoadjuvant treatment for early stage triple-negative breast cancer Atezolizumab (Tecentriq; MPDL3280A) , Nab-Paclitaxel (Abraxane; ABI 007; ABI-007) Breast cancer Breast Cancer 2018 View  |  Download
Atezolizumab in combination with cobimetinib for BRAF wild-type metastatic melanoma – first line Atezolizumab (Tecentriq; MPDL3280A) , Cobimetinib (Cotellic; GDC-0973; cobimetinib hemifumarate) Melanoma Skin Cancer 2018 View  |  Download
Atezolizumab in combination with chemotherapy for non-small-cell lung cancer- neoadjuvant and adjuvant Atezolizumab (Tecentriq; MPDL3280A) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
1 2 80 81 82 83 84 87 88
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications